1 of 1
Story summary
- A glucagon-like peptide-1 (GLP-1) drug study found Ozempic and Zepbound likely have little to no impact on obesity-related cancers, including breast and pancreatic cancer.
- The analysis included 94,245 adults with obesity or type 2 diabetes.
- Follow-up lasted about 70 weeks, and researchers urged longer-term studies.
- Experts say the results are reassuring because they show little cancer risk and most patients use these drugs for weight management.
